Galapagos avoids 'complete whiff' as key anti-inflammatory drug fails to beat placebo in midphase trials

After talking up its anti-inflammatory therapies for years, Galapagos is switching gears to preclinical SIK inhibitors after the lead compound in the critical program delivered underwhelming midphase data.

The Belgian biotech is advancing other molecules against a target that has become vital to its future as other pipeline prospects have flamed out.